- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
| 30.05. | Femasys Announces $4.5 Mln Offering Through Public Sale And Private Placement Of Shares | 1 | RTTNews | ||
| 30.05. | Femasys announces pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5M | 2 | Seeking Alpha | ||
| 30.05. | Femasys Inc.: Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million | 3 | GlobeNewswire (USA) | ||
| 29.05. | Femasys plans stock offering and private placement | 1 | Investing.com | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 29.05. | Femasys announces public offering, concurrent private placement | 1 | Seeking Alpha | ||
| 29.05. | Femasys plant Aktienangebot und Privatplatzierung | 2 | Investing.com Deutsch | ||
| 29.05. | Femasys Inc.: Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 23.05. | Femasys droht Delisting von der NASDAQ | 1 | Investing.com Deutsch | ||
| 23.05. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Jones Trading cuts Femasys stock target to $6, maintains Buy | 1 | Investing.com | ||
| 09.05. | Analyst Expectations For Femasys' Future | 2 | Benzinga.com | ||
| 09.05. | Femasys stock price target cut to $12 from $15 by H.C. Wainwright | 3 | Investing.com | ||
| 09.05. | Femasys GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
| 08.05. | FEMASYS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Femasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update | 51 | GlobeNewswire (Europe) | -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full... ► Artikel lesen | |
| 08.05. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 02.04. | Femasys reports FY results | 1 | Seeking Alpha | ||
| 28.03. | H.C. Wainwright maintains Femasys stock Buy rating, $15 target | 1 | Investing.com | ||
| 27.03. | FEMASYS INC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 488,00 | -0,15 % | What Makes Intuitive Surgical (ISRG) an Investment Bet? | ||
| UNITEDHEALTH | 266,05 | 0,00 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: UnitedHealth, Flatexdegiro und Friedrich Vorwerk! | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 10:00 Uhr, Deutschland: Friedrich... ► Artikel lesen | |
| ROKU | 68,76 | -0,16 % | Roku TV sluggish? My go-to fix can revitalize its performance in just seconds | ||
| ATOSSA THERAPEUTICS | 0,800 | +8,40 % | Ascendiant Capital raises Atossa Genetics stock price target to $7.50 | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| CENTENE | 48,245 | -0,28 % | Aktie von Centene büßt 4,00 Prozent ein (47,4008 €) | An der US-amerikanischen Börse notiert das Wertpapier von Centene derzeit ein wenig leichter. Der jüngste Kurs betrug 54,18 US-Dollar. Für Inhaber von Centene ist der heutige Handelstag bisher nicht... ► Artikel lesen | |
| VERU | 0,525 | -3,40 % | Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ... | --Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial... ► Artikel lesen | |
| QUIDELORTHO | 25,400 | -2,31 % | Quidel auf der Jefferies-Konferenz: Strategische Neuausrichtung und Wachstumspläne | ||
| TEMPEST THERAPEUTICS | 5,240 | -100,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| NANO-X IMAGING | 5,530 | +7,80 % | Nano-X Imaging LTD.: Nanox Receives MDR CE Mark for HealthOST, an Advanced AI-Powered Software for Spine Assessment | HealthOST identifies vertebral height loss and bone mineral density, which are key indicators of musculoskeletal diseaseOsteoporosis is a common progressive bone disease among adults over 50 years of... ► Artikel lesen | |
| FULGENT GENETICS | 18,100 | -4,23 % | Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology | ||
| LANTHEUS | 70,76 | -1,17 % | Lantheus Holdings, Inc.: Lantheus Announces Sale of SPECT Business to SHINE Technologies | Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 3,020 | +3,42 % | RBC Capital raises Perspective Therapeutics stock price target to $16 | ||
| AMN HEALTHCARE SERVICES | 17,500 | +5,42 % | AMN Healthcare Services Inc: AMN Healthcare Announces First Quarter 2025 Results | Quarterly revenue of $690 million; GAAP loss of ($0.03)/share and adjusted EPS of $0.45 DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator... ► Artikel lesen | |
| OMNICELL | 27,400 | 0,00 % | Is it Apt to Retain Omnicell Stock in Your Portfolio Now? |
Das Unternehmen FEMASYS INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.